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Abstract: Subarachnoid hemorrhage (SAH) is a life-threatening stroke caused by bleeding in the 
subarachnoid space. Delayed cerebral ischemia, a risk factor for death during non-traumatic SAH 
treatment, is often prevented by inducing hemodynamic augmentation through the administration 
of vasopressors. The three common vasopressors administrated to SAH patients are dopamine, 
phenylephrine, and norepinephrine. A recent study using Electronic Health Records (EHR) of non-
traumatic SAH patients identified that the administration of phenylephrine is associated with lower 
hospital mortality; however, this study did not consider heterogeneity in treatment effects.  
Therefore, the goal of this paper is to study the heterogeneity in vasopressor treatment effects by 
exploratory subgroup analyses. The subgroups were identified by studying the vasopressor and 
pretreatment covariates interaction effects. We employed a machine learning and a generalized 
linear model approach to study the interaction effects. We also employed propensity scoring and 
 inverse probability weighting to minimize the confounding and selection biases in treatment effect 
estimates due to inherent pretreatment group differences in the data. Our results showed that 
dopamine had the highest mortality among those who did not have ondansetron ( a pretreatment 
medication used to prevent nausea) compared to phenylephrine and norepinephrine; whereas 
norepinephrine has the highest mortality among those who had ondansetron compared to 
phenylephrine and dopamine. However, for the subgroup who did not have ondansetron but had 
fentanyl and lidocaine, there was no significant difference in the mortality rate between 
vasopressor treatment group. Overall, those who had ondansetron had better survival compared to 
those who did not have ondansetron with respect to all the three vasopressors.
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Study Background 
 
Stroke and SAH 
 
Stroke is the fifth leading cause of death in 2016, and it accounts for 1 in 20 deaths across 
the United States (U. S.). 4 Two main types of stroke are ischemic stroke and hemorrhagic stroke. 
Ischemic stroke is a common stroke caused by a blood clot that blocks a blood vessel in the brain. 
It accounts for 80% of all cases and it transpires because of oxygen deprivation in the brain. In 
comparison, a hemorrhagic stroke occurs when a   blood vessels ruptures, and bleeds into the 
intracerebral space (referred to as intracerebral hemorrhage, ICH) or subarachnoid space (referred 
to as subarachnoid hemorrhage, SAH). SAH constitutes 5-10% of strokes annually reported in the 
U. S.1 SAH can occur due to trauma or non-trauma conditions, differing in their underlying 
pathophysiology. Among the non-trauma SAH cases, 85% is due to a ruptured aneurysm, while 
the remaining 15% are due to nonaneurysmal perimesencephalic bleeding and other causes.3 The 
estimated incidence of nontraumatic SAH in the U. S. during 1979-2008 was 7.2 to 9.0 per 100,000 
per year.2 Metanalysis of 51 studies through October 2005 showed a worldwide incidence of 
nontraumatic SAH of approximately 9 per 100,000 person-years.5 
A retrospective cohort study of non-traumatic SAH patients reported an in-hospital 
mortality rate of 14%.2 Concurrently during SAH, patients can also experience delayed cerebral 
ischemia (DCI), one of the primary causes of in-hospital mortality. DCI is linked to cerebral 
vasospasm, a vascular constriction of cerebral vessels after SAH. Usually, between 20-40% of the 
SAH patients would develop cerebral vasospasm.6 Among those affected, 50% will die or suffer 
permanent neurological damage.6 However, DCI in patients presenting with SAH could often be 
prevented by inducing hemodynamic augmentation to maintain cerebral perfusion. Administration 
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of vasopressors is a widely held medical practice for inducing hypertension.7,8 Three common 
vasopressors administered are dopamine, phenylephrine, and norepinephrine, but which of these 
vasopressors should be chosen as the first-choice treatment still remains unknown.  
Currently, no prospective comparative study on vasopressor treatment choice for SAH patient are 
available. However, it is believed that vasopressor choice is patient specific, and it depends on the 
one’s prior diagnosis and medication.9 A recent retrospective study, I have been a part of, using 
the Cerner Health Facts Electronic Health Records (EHR) data (n=2535) found that phenylephrine 
is associated with lower hospital mortality (under review). However, we cannot generalize this 
observation to all subjects because each subject may have a different treatment response. 
Therefore, the goal of this paper is to study the differential effect  of vasopressor by exploratory 
subgroup analyses.  
Electronic Health Record (EHR), Cerner Health Facts 
 
EHR is a longitudinal electronic record of patient health information generated by one or more 
encounters in any healthcare delivery setting.14 Although EHR has been primarily used for 
structured billing and records, with advances in big data analysis and machine learning 
methodologies, it is now being utilized for quantitative analysis to improve patient care and to 
identify optimal treatments or treatment strategies, including outcomes research and 
epidemiological studies. A major provider for the EHR systems in the U. S. is the Cerner 
Corporation in North Kansas City, Missouri.15 In this study, we used the SAH patient records from 
the Cerner health facts database hosted by SBMI (School of Biomedical Informatics) at UT Health 
Science Center. This is a publicly available relational database comprising of multicenter de-
3 
 
identified 106 million health records. The data contain patient records across 700 participating 
Cerner client hospitals and clinics from 2000 to 2015 in the U. S. 
EHR includes individual patient records on demographics, diagnosis history, medication history, 
clinical procedure, vital signs, lab records, and billing information. Each patient record follows the 
key standards for clinical vocabularies, such as Current Procedure Terminology (CPT) codes for 
clinical procedures, International Classification of Diseases (ICD) for diagnoses and Logical 
Observation Identifiers, Names and Codes (LOINC) for ordering lab tests. Since these standards 
are implemented uniformly across medical institutions, patient data from different institutions can 
be combined to make nationally representative data. Aggregated EHR data such as Cerner health 
facts then give access to a large amount of data that are useful for studying rare events such as 
SAH. EHR data also have a large number of variables that can be studied simultaneously. For 
issues such as missing data and data quality16,17  in the EHR data and the presence of correlated 
covarites, an appropriate staitical method such lasso modeling and propensity scring were 
employed in our analysis.  
Specific Aims 
The objective of this thesis is to identify patient subgroups for which vasopressor has 
differential treatment outcomes. Identifying these patient subgroups would help to inform the 
optimum vasopressor choice among dopamine, phenylephrine, and norepinephrine from a patient-
specific perspective. The differential effect of vasopressor treatment for SAH patients was studied 
by exploratory subgroup analyses in this paper. To conduct subgroup analyses, we utilized two 
approaches: a generalized linear model and a machine learning approach.  In the generalized linear 
model approach, we employed lasso regression for feature selection; and applied propensity 
scoring to reduce the effects of observed confounding and to obtain unbiased estimates of the 
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average treatment effects. False Discovery Rate (FDR) approach22 was then used to correct for 
multiple comparisons. We also employed a machine learning method, a recursive partitioning 
method for classification and regression. The theory behind lasso, propensity scoring, and 
recursive partitioning method are discussed in the Methods section. 
The specific aims are as follows: 
1. Conducting a statistical, retrospective exploratory subgroup analysis of vasopressor 
treatment effects in SAH patients on mortality outcome via a generalized linear model 
(GLM) approach: 
a. Constructing  covariate balanced data using propensity score modeling and inverse 
probability treatment weighting. 
b. Identifying demographic, medication, and vital sign variables associated with 
patient mortality.  
c. Identifying significant interactions between different vasopressor treatments and 
covariates, adjusting for variables selected in 1b. Interaction p-values were adjusted 
for multiple testing. 
d. Studying the magnitude of treatment effect among the subgroups identified through 
significant interaction effects.  
2. Conducting a machine learning, data-driven tree-based recursive partitioning approach 
to explore heterogeneity in vasopressor treatment effects. 
3. Comparing the subgroups from (1) GLM and (2) machine learning approaches 
We hypothesize that there is an interaction effect of pretreatment covariates on the 
relationship between vasopressor treatment effect and mortality. Any identified interaction effect 
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will show the presence of subgroups within the SAH patients. This could then generate potential 
new hypotheses for future studies of personalized medicine in SAH patients receiving vasopressor 
treatments. 
Public Health Significance 
SAH patients have a high mortality rate.  Currently, patients are mainly treated using three 
vasopressors: dopamine, phenylephrine, and norepinephrine. In the absence of clinical trials on 
vasopressor choice, the decision has often to be made by physicians based on their experience and 
the patient’s hemodynamic status, comorbid conditions, and institutional preferences, which may 
affect patient outcomes after the diagnosis of SAH. The data-driven subgroup analysis using the 
EHR data in this study can then highlight the differences in different patients’ responses to 
vasopressor treatment. Results from our analysis can be used as hypothesis generating for the 
guideline in designing future clinical trials; and choosing the optimal vasopressor for a group of 
SAH patients. In the long term, our study also has the potential to improve SAH treatment and 
reduce the mortality rate among SAH paitents. 
Method 
Subgroup analysis is a topic of great interest specifically with an eye towards more 
personalized medicine. It is useful in determining the heterogeneity of treatment effects, and it is 
critical to identify the positive and negative effects of the treatment. Subgroup analyses can be 
conducted either  as pre-specified or during post-hoc reviews. In a pre-specified subgroup analysis, 
hypotheses about which subgroups to examine are predefined. In clinical trials, subgroups are often 
defined at the design stage based on prior insights or the exploratory analyses of other datasets. In 
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this thesis, we will conduct an exploratory analysis for subgroup identification by examining all 
possible subgroups.  
  However, there exist several limitations and pitfalls of post-hoc subgroup analyses. A 
major limitation of a subgroup analysis is its risk of increasing the probability of finding 
statistically significant findings due to chance. Due to multiple tests, a study can run into a risk of 
false positives during the post hoc analysis. Nevertheless, multiplicity correction using FDR can 
reduce this effect. Moreover, if we test the statistical interaction between treatment and some 
subgroups first, and then test within the subgroups only if a certain interaction is significant, we 
could reduce the number of tests conducted. So, in this thesis, we used both multiplicity correction 
and limited number of tests to avoid false positive during the post hoc analysis. 
Subgroup analysis can also lead to false negatives due to inadequate power. Brookes ST et 
al10, used a simulation study to quantify the power of interaction test in trials designed to detect 
the overall treatment effects. They looked at different scenarios of the overall treatment and 
subgroup effects using both continuous and binary outcomes, and they found that if a trial has 80% 
power for the overall effect, the power to detect the interaction effect of the same magnitude is 
only 29%. They also pointed out that to detect the interaction effect of the same magnitude with 
the same power as the overall effect, the sample size needs to be fourfold.10 However, even with 
these limitations, subgroup analyses are still often conducted to extract information from data for 
hypothesis generation. Of course, one has to follow several guidelines while reporting and 
interpreting the results.11,12,13 Therfore, in this thesis, to identify subgroups, we evaluated multiple 
covariate interaction effects on vasopressor treatment choices for a SAH patient outcome model.  
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When constructing the SAH patient outcome model to account for confounding, it would 
be appropriate to incorporate as many variables as available.  However, there is a risk of overfitting 
the model, resulting in a numerically unstable estimate.  Overfitting could also reduce the power 
of prediction for future data due to the presence of noise18,19 and violation of the principle of 
parsimony. A parsimonious model should include no more predictors than necessary. Peduzzi et 
al20 proposed a guideline regarding the number of predictors that should be included in statistical 
models. This guideline suggests including at least 10 outcomes of each type for every independent 
variable to avoid over-estimated and under-estimated variance. Hosmer and Lemeshow21 
suggested the number of parameters (𝑝 + 1) in a logistic regression model should be ≤
min(𝑛0, 𝑛1) /10, where, 𝑛1 is the number of events of type 1, and 𝑛0 is the number of events of 
type 2 of a binary dependent variable. In the SAH data, 𝑛1= 1895 and 𝑛0 = 2720; hence, by above 
mentioned criteria, we could include a maximum of 189 parameters. Hence it is important to 
choose an appropriate statistical method to find important predictors to fit a parsimonious model. 
Another important issue that needs to be addressed is confounding. Confounding occurs if the 
SAH patients who received one vasopressor differed systematically from those receiving a 
different vasopressor in terms of pretreatment covariates. However, this could be addressed by 
removing or minimizing the effect of confounding through choosing a suitable statistical method 
such as propensity scoring. 
 
Overview of the proposed analysis 
 
Generalized linear models and machine learning approaches are used to identify the significant 
interaction effect between vasopressor and pretreatment covariates within the SAH patient data. 
The generalized linear model analysis included four steps. First, the propensity score, which is 
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defined as the probability of receiving a treatment conditional on observed pretreatment covariates. 
It was calculated using Generalized Boosted Models (GBM), a flexible estimation method that can 
adjust for many pretreatment covariates.23 Prior to GBM, we used the L1-penalized multinomial 
logistic regression (GLM Multinomial Lasso) to identify important factors associated with 
vasopressor treatment. These selected variables were used as input variables in GBM to obtain the 
propensity score. Obtained scores were then used as weights in the mortality outcome model whicn 
test for interactions in the third step. The second step involved using L1-penalized logistic models 
(GLM Logistic Lasso) to select the important factors associated with mortality. The selected 
variables were then used as the main effects for the outcome model in the third step. In the third 
step, a base outcome model was constructed using weights from the first step, the main effects 
from the second step and the vasopressor treatment variable. Further, an interaction model was 
also constructed with the treatment interaction with each main effect covariate identified from the 
second step. Finally, the base model and interaction model were compared using the Likelihood 
ratio test (LRT). In order to account for the multiplicity correction in LRT, the FDR adjusted p-
value was used to identify significant interaction effects. Any significant interactions identified 
would highlight the difference in the effect of vasopressor on mortality conditional on the presence 
or absence of that main effect. Further, we conducted Model-based Recursive Partitioning (MOB), 
a machine learning approach for subgroup analysis. We then compared the generalized linear 
model result with the MOB result. 
Data Summary 
 
In this study, we used the SAH patient records queried from the Cerner Health Facts® database. 
This database is hosted by SBMI, UT Health Science Center and accessed through an appropriate 
IRB approval (IRB HSC-MS-18-0124). Our data included de-identified patient-level electronic 
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health records from 700 hospitals and clinics that use Cerner Corporation’s EHR system. These 
correspond to 39,017 patients with at least one SAH encounter.  
Inclusion/Exclusion criteria: From the 39,017 SAH patient records, our study population was 
identified based on the following criteria: (1) Only records with diagnosis history on ICD-9 code 
(430,800.2x, 800.7x, 801.2x, 801.7x, 803.2x, 803.7x, 804.2x, 804.7x, 852.x) with medication 
history of at least one of the vasopressor medications norepinephrine, phenylephrine or dopamine 
were included (N=4,850). (2) SAH patients below the age of 17 were excluded.  (3) SAH patients 
who received multiple vasopressor treatments simultaneously as initial treatment were excluded 
(n=40). (4) SAH patient who had a diagnosis of the traumatic cause of SAH were excluded 
(n=2176). 
Date cleaning: Observations with Mortality = “Unknown” (n=93), Gender = “Unknown” (n=2)  
and those with missing medication information were all omitted from the analysis.  Further, 
pretreatment medication variables with less than 10 occurrences were also excluded.   
Study population: The study population included non-traumatic SAH patients over the age of 17 
with a single encounter or multiple encounters for SAH (N= 2415). When a patient had multiple 
encounters separated by less than a day, the encounters were then combined into a single encounter 
otherwise only data from the first encounter were used in the analysis. A subsample of size N= 
940 included the data of baseline heart rate, baseline systolic and diastolic blood pressure, and all 
these data were used for sensitivity analysis. 
Exposure: The primary exposure of interest is the first vasopressor administered to eligible 
patients, either phenylephrine, dopamine, or norepinephrine.  
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Outcome: The outcome for this study is the mortality rate which is defined as death at hospital or 
discharge to hospice. Mortality will be coded as 1 (death or discharge to hospice) and 0 (survived).  
Our final cleaned data consisted of 2,415 patients’ records, and each was identified using an 
individual identifier (variable Patient_SK). The data also included age in years, race (African 
American=549, White= 1609, other = 257), marital status (divorced=258, married= 1098, single= 
637, widowed=180, unknown= 242), gender (female=1536 , male=879), mortality, vital signs 
(heart rate, systolic blood pressure and diastolic blood pressure) and total fluids administered 
(sum_IVF). Appendix I shows a summary of all the variables. Additionally, in the Cerner database, 
because we did not have timing information for diagnoses, we could not differentiate whether the 
observed diagnoses were pretreatment or post-treatment factors. Hence, diagnosis factors were not 
included in our analysis. 
Statistical Analysis 
 
The analysis was performed using R software (R Foundation for Statistical Computing, Vienna, 
Austria).  Specifically, we used ANOVA or Kruskal-Wallis test to compare the continuous 
variables among the vasopressor treatment groups. For categorical factors, we used the Chi-square 
test. The following subsection describes the various statistical methods used in our analysis. 
Least absolute shrinkage and selection operator (Lasso) 
L1-penalized regression (also referred to as Lasso) was used to select the important factors 
associated with the dependent variable of interest. We applied Lasso prior to GBM and the 
treatment-covariate interaction studies to identify the important factors associated with 
vasopressor and mortality, respectively. Lasso is a regularization and feature selection method first 
formulated by Robert Tibshirani in 1996. In high dimensional data such as EHR where the number 
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of features is larger than the number of observations, a sparse statistical model such as lasso would 
be appropriate since it involves regularization techniques of penalizing the absolute size of the 
regression coefficients. Lasso shrinks the less important feature’s coefficient to zero, thus 
removing some less important features altogether. The purpose of the shrinkage is to prevent 
overfit arising due to collinearity of the covariates or high-dimensionality. Lasso could minimize 
the sum of squared error subject to an 𝑙1 penalty term  𝜆 ∑ |𝛽𝑗|
𝑘
𝑗
 , where λ ≥ 0 is a tuning parameter. 
When λ =0, the Lasso estimate is equivalent to the least squares estimate. When λ is sufficiently 
large, coefficients are forced to be exactly equal to zero, which help us attain dimensionality 
reduction. 
Lasso estimator for GLM 
 
The Generalized Linear Models (GLM) is a broad class of the linear regression models that allow 
analysis of different types of univariate response. Standard linear regression is a special case of 
GLM for the normally distributed continuous response; likewise, logistic regression is GLM for 
binary response, and log-linear regression is GLM for counts data. GLM consists of three main 
components: 
1. Random component: GLM assumes that the probability distribution of the response variable is 
from an exponential family distribution including normal, Bernoulli, binomial and Poisson 
distributions. The random component defines a probability distribution for the response variable, 
𝑌𝑖. In a logistic regression model, the probability distribution of the response variable follows a 
Binomial distribution. 
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2. Systematic component: Systematic component specifies the effect of an explanatory variable on 
the mean of Y, which can be expressed as a linear combination of these predictors: 
𝜂 = 𝛽0 + 𝛽1𝑋1 +  𝛽2𝑋2 +  … + 𝛽𝑘𝑋𝑘  
2. Link function: This component specifies a function g(.) that relates the expected value of Y, 𝜇 
to the linear predictors. That is, a link function connects the systematic and random component as 
𝑔(𝜇) =  𝛽0 + 𝛽1𝑋1 +  𝛽2𝑋2 +  … + 𝛽𝑘𝑋𝑘  
For logistic regression, the link function is the logit function. 
𝑔(𝜇) = 𝑙𝑜𝑔𝑖𝑡(𝜇) = log (
𝜇
1 − 𝜇
) = 𝛽0 + 𝛽1𝑋1 +  𝛽2𝑋2 +  … + 𝛽𝑘𝑋𝑘  
 
For GLM, lasso estimator is defined by penalizing the negative log-likelihood with the 𝑙1-norm. 
The negative log-likelihood is 
− ∑ log (𝑝𝛽(𝑌𝑖|𝑋𝑖))
𝑛
𝑖=1                                                     (1) 
The equation (1) in terms of the loss function can be expressed as  
𝑛−1 ∑ 𝜌𝛽(𝑋𝑖, 𝑌𝑖)
𝑛
𝑖=1                                                                 (2) 
𝜌𝛽(𝑥, 𝑦) =  −log (𝑝𝛽(𝑦|𝑥))                                                   (3) 
Then, the 𝑙1-norm penalized Lasso estimator is defined as 
?̂?(𝜆) =  𝛽
𝑎𝑟𝑔𝑚𝑖𝑛  (𝑛−1 ∑ 𝜌𝛽(𝑋𝑖, 𝑌𝑖)
𝑛
𝑖=1 +  𝜆 ‖𝛽‖1)                                (4) 
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For a logistic regression where 𝑌𝑖|𝑋𝑖 ~ 𝐵𝑖𝑛𝑜𝑚𝑖𝑎𝑙 (1, 𝜇𝑖),  the negative log-likelihood equals 
− ∑ log (𝑝𝛽(𝑌𝑖|𝑋𝑖))
𝑛
𝑖=1 =  ∑ {−𝑌𝑖𝑓𝛽(𝑋𝑖) + 𝑙𝑜𝑔 (1 + 𝑒𝑥𝑝 (𝑓𝛽(𝑋𝑖)))}
𝑛
𝑖=1         (5) 
Where 𝑓𝛽(𝑋𝑖) =  𝑙𝑜𝑔𝑖𝑡(𝜇) = log (
𝜇
1−𝜇
) =  ∑ 𝛽𝑗𝑥𝑗
𝑘
𝑗=0 , and the corresponding loss function for (5) 
is  
𝜌𝛽(𝑥, 𝑦) = −𝑦 (∑ 𝛽𝑗𝑥𝑗
𝑘
𝑗=0
) + 𝑙𝑜𝑔 (1 + 𝑒𝑥𝑝 (∑ 𝛽𝑗𝑥𝑗
𝑘
𝑗=0
)) 
Then, the lasso estimator for the logistic model is defined as that in (4). 
Propensity Score (PS) 
 
One of the challenges in the analysis of observational data such as EHR is the presence of 
confounding bias. Because treatments were not given randomly, confounding can occur if the 
underlying distribution of pretreatment covariates differ between the vasopressor treatment 
groups. Hence, direct comparisons between the groups could result in a biased estimate of 
treatment effects.24 However, propensity scoring (ps) methodology can be used to create 
comparison groups which have similar values for observed confounders. In this way, the effect of 
the type of treatment received could be isolated. PS was first introduced by Rosenbaum and Rubin 
in 1983. It is defined as the conditional probability of assignment to a treatment given a vector of 
observed covariates.24  The propensity score, 𝑒(𝑋𝑖)  for the subject i, is given by 
𝑒(𝑋𝑖) = 𝑃(𝑍 = 𝑘|𝑋𝑖) 
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where Z = k denotes kth treatment, and 𝑋𝑖 is the covariate matrix of that subject, and it is assumed 
that  X’s and Z’s are independent.25 PS modeling also requires positivity and exchangeability 
assumptions. The positivity assumption states that all the subjects should have a non-zero 
probability of receiving each treatment. A lack of overlap in the true distribution of pretreatment 
characteristics between treatment groups implies a violation of this assumption. Exchangeability, 
also called ignorable treatment assignment assumption, assumes that all true confounders are 
measured and observed. This condition assumes that the set of observed pretreatment covariates is 
sufficiently rich, and it includes all variables directly influencing both treatment and outcome.23 
However, it is not possible to test this assumption. In this study, this assumption is violated, 
because we could not include morbid and co-morbid factors due to the inherent nature of the data. 
Causal-Estimands: 
Average Treatment Effect (ATE) and Average Treatment Effect Among the Treated (ATT) are 
two types of causal effect estimands that can be used to derive a summary measure of treatment 
effect. The definition of ATE and ATT are slightly different, and the choice of this estimand 
depends on the research question and the target population under treatment. ATE is a better 
estimand if every member in the study population has equal opportunity to receive treatment. 
However, ATT is the choice of estimand if the research question of interest is to study the 
effectiveness of one treatment and if it were replacing an alternate form of treatment. Clearly, in 
our analysis, ATE was the choice of estimand since it is plausible that every SAH patient had an 
equal chance of receiving one of the three vasopressors, and the research question focuses on the 
relative effect of three vasopressors on the outcome, mortality. Moreover, in a binary treatment 
setting, ATE of a treatment (T) relative to a control (C) is the difference in the mean outcome, had 
the study population was administrated T versus C. Likewise, in a setting with 3 treatments, there 
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exist three pairwise ATEs, and they can be interpreted as the difference in mean outcomes had the 
study population was administrated one treatment k vs. a different treatment ?̀?. ATE can be 
calculated as below26 
𝐴𝑇𝐸𝑘,?̀? =  𝐸 (𝑌(𝑘) − 𝑌(?̀?)) =  𝐸(𝑌(𝑘)) − 𝐸(𝑌(?̀?)) 
After defining the casual estimands appropriate for the research question, we can adjust for the 
estimated propensity scores in one of the four ways: matching, stratifying, weighting and covariate 
adjustment. In our analysis, we applied weighting via Inverse Probability Treatment Weights 
(IPTW) of subjects to create a synthetic sample in which treatment assignment is independent of 
the measured pretreatment covariates.27 The idea behind IPTW is to up-weight those who are 
underrepresented and down-weight those who are overrepresented.23 The weight of a treated 
subject is defined as the inverse of its propensity score (𝑤𝑖 = 1/𝑒(𝑋𝑖), and the weight of a control 
subject is defined as the inverse of one minus its propensity score (𝑤𝑖 = 1/(1 − 𝑒(𝑋𝑖))). 
PS estimation for multiple treatments: 
Imbens34 extends Rosenbaum and Rubin’s work to multiple treatment cases by introducing the 
concept of the generalized propensity score. The generalized propensity score r (t, X) is the 
conditional probability of receiving treatment t given the pre-treatment variables X, 
𝑟(𝑡, 𝑋) = 𝑃(𝑇𝑖 = 𝑡| 𝑋𝑖) =  𝐸{𝐼(𝑡)|𝑋 =  𝑋} 
where T denotes the treatment received and takes on a value in a set T, and I(t) is the indicator of 
receiving treatment t. Unbiased estimation of average treatment effects conditioning on the 
generalized propensity score requires the assumption of weak ignorability. Weak ignorability is 
defined as pairwise independence of the treatment assignment and potential outcomes.35 If weak 
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ignorability holds, the inverse of the generalized propensity scores at each treatment level can be 
used as weights to estimate the mean potential outcome, 𝜇?̂? for each treatment level as shown 
below 
𝜇?̂? =  
∑ 𝑇𝑖[𝑡]𝑌𝑖𝑤𝑖[𝑡]
𝑛
𝑖=1
∑ 𝑇𝑖[𝑡]𝑤𝑖[𝑡]
𝑛
𝑖=1
 
Where 𝑤𝑖 = 1/𝑃(𝑇𝑖 = 𝑡| 𝑋𝑖)  
Using GBM to obtain PS: 
 
PS for multiple treatments can be estimated using multinomial regression or machine learning 
methods. Considering the high dimensional nature of the SAH data, we used a machine learning 
approach based on trees called the generalized boosted model (GBM). GBM can typically obtain 
robust propensity score weights with better balance properties than the multinomial logistic 
method.23 GBM estimation involves an iterative process with multiple regression trees to capture 
complex and nonlinear relationships between treatment assignment and the pretreatment 
covariates without over-fitting the data.23 GBM is fit to separate pairs of treatments which consider 
one treatment as a holdout and estimates 𝑃(𝐼𝑖(𝑡)|𝑋), where 𝐼𝑖(𝑡) = {1 if 𝑇𝑖 = 𝑡, 0 otherwise} 
using the estimated odds ratios of the probability assigned to each treatment versus the probability 
assigned to the holdout treatment. Depending on the choice of holdout treatment, the estimated 
probabilities might differ since this method relies on the binary estimation of the subsamples of 
the population. The estimated propensity scores from each of the GBM fits is used to compute the 
weights. McCaffrey states that the general intuition behind this approach is that, for any given 
treatment, 𝑇𝑖 = 𝑡, estimating weights for a treatment group only requires knowing the probability 
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that each case assigned to this group received that assignment rather than one to any other 
treatment23. 
 
We also used Toolkit for Weighting and Analysis of Nonequivalent Groups (twang 1.3) 
packages in R for evaluation of propensity scores and associated weights. The multinomial 
propensity scores (mnps) function in this package can handle more than two treatment conditions, 
and it relies on GBM to generate numerous regression trees for estimating the propensity score 
model, which could lead to the best balance between the treated and reference groups.23 In mnps, 
the GBM is fitted to separate pairs of treatment, not to a multinomial model such as that in a 
multinomial logistic regression model. Then, the estimated propensity scores from each of the 
GBM fits are used to compute the weights. GBM uses stopping rules to select optimal iterations 
to yield the best balance. These are based on summary statistics (mean, max) of the absolute 
standardized mean difference (es) or the Kolmogorov Smirnov (ks) statistic. For covariate k (k = 
1, … K) and treatment t (t = 1, … M), the population standardized mean difference, 𝑃𝑆𝐵𝑡𝑘 is given 
by23 
𝑃𝑆𝐵𝑡𝑘 =  
|𝑋𝑘𝑡̅̅ ̅̅ − 𝑋𝑘𝑝̅̅ ̅̅ ̅|
𝜎𝑘?̂?
⁄  
Where 𝑋𝑘𝑡̅̅ ̅̅   is the propensity score weighted mean of the covariate, 𝑋𝑘𝑝̅̅ ̅̅ ̅  and 𝜎𝑘?̂? the unweighted 
mean and standard deviation of the covariate for the pooled sample across all treatments. This 
statistic measures the similarity of each treatment group to the population in terms of covariate 
means both before and after weighting. Population KS (PKS) statistic for assessing balance with 
multiple treatments is given by23 
𝑃𝐾𝑆𝑡𝑘 =
𝑠𝑢𝑝
𝑥
|𝐸𝐷𝐹𝑡𝑘(𝑥) − 𝐸𝐷𝐹𝑝𝑘(𝑥)| 
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 Where 𝐸𝐷𝐹𝑡𝑘(𝑥) =  ∑ 𝐼(𝑋𝑖𝑘 ≤
𝑛
𝑖=1 𝑥)/𝑛 is the unweighted empirical distribution function for the 
pooled sample across all treatments. 
 
Assessing Covariate Balance: 
After calculating IPTW, it is important to assess the balance. Treatment groups are considered 
balanced if the absolute standardized mean differences are less than about 0.2. The “plot ()” 
function was used to assess the balance graphically. 
 
GLM approach for subgroup analysis 
 
The first step in the GLM approach for subgroup analysis was using a lasso to identify the 
covariates that were associated with treatment response.  Glmnet package was used to implement 
logistic regression modeling with the lasso penalty. The binary outcome variable, mortality, was 
coded as 1 (death at hospital discharge or discharge to hospice), and 0 (survived), and the treatment 
is coded as 1 (=Dopamine), 2 (=Phenylephrine), 3(=Norepinephrine). The covariates include 
demographic factors (age, race, gender and marital status) and pretreatment medications. The base 
model obtained after lasso penalized feature selection will be of the form below 
Pr(𝑌 = 1|𝑋) = log (
𝜇
1 − 𝜇
)
= 𝛽0 +  𝛽1𝐷𝑜𝑝𝑎𝑚𝑖𝑛𝑒 +  𝛽2𝑁𝑜𝑟𝑒𝑝𝑖𝑛𝑒𝑝ℎ𝑟𝑖𝑛𝑒 + 𝛽3𝑋𝑐1 +  … . . +𝛽𝑘𝑋𝑐𝑘 
 where 𝑋𝑐1 … . 𝑋𝑐𝑘 represent selected covariates using lasso penalized feature selection.  
In order to identify the differential effect of treatment among the selected covariates, the treatment-
covariates interaction effect for each covariate is included in the base model. For selected covariate 
𝑋𝑐1 , the interaction model will of the form below 
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Pr(𝑌 = 1|𝑋) = 𝛽0 + 𝛽1𝐷𝑜𝑝𝑎𝑚𝑖𝑛𝑒 + 𝛽2𝑁𝑜𝑟𝑒𝑝𝑖𝑛𝑒𝑝ℎ𝑟𝑖𝑛𝑒 + 𝛽3𝑋𝑐1 +  … . . +𝛽𝑘𝑋𝑐𝑘
+ 𝛽𝑘+1𝐷𝑜𝑝𝑎𝑚𝑖𝑛𝑒 × 𝑋𝑐1 +  𝛽𝐾+2𝑁𝑜𝑟𝑒𝑝𝑖𝑛𝑒𝑝ℎ𝑟𝑖𝑛𝑒 × 𝑋𝑐1  
Similarly, the treatment-covariates interaction effect was studied for every selected covariate. The 
base model and interaction model were then compared using a likelihood ratio test. To correct for 
multiple comparisons, we used the false discovery rate (FDR) approach. 
Machine learning approach for subgroup analysis using MOB 
Model-based Recursive Partitioning (MOB) is a tree-based recursive partitioning method 
proposed by Zeileis et al.28 MOB combines both regression modeling and tree structure for 
automated detection of the patient subgroup. This involves fitting an M-type parametric model at 
terminal nodes of the tree structure. Like other methods based on classification and regression trees 
(CART), MOB also uses recursive partitioning methods to create a decision tree. CART finds 
optimal cuts or dichotomizations in variables, and then finds the best cut among the groups created 
by previous cuts, hence identifying higher-order covariate interactions.29 MOB is more suitable 
for subgroup analysis since it restricts interactions to treatment × covariate interactions.  
  MOB algorithm works by fitting a logistic regression model with mortality as the response 
variable and vasopressor treatment as a control variable, and it fits on all observations using 
maximum likelihood estimation. For n observation of 𝑌𝑖 , (𝑖 = 1, … 𝑛) the parametric model can 
be fitted, and its parameter estimate 𝜃 can be calculated by minimizing objective function 
𝛹(𝑌, 𝜃) such that 
𝜃 =  𝜃
𝑎𝑟𝑔𝑚𝑖𝑛  ∑ 𝛹(𝑌𝑖, 𝜃𝑖)
𝑛
𝑖=1
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Further, the algorithm tries to detect pretreatment covariate effects by testing parameter 
instability. The parameter instability was assessed with respect to each pretreatment covariate 
while controlling for the vasopressor treatment. The parameter instability was assessed to 
determine which variable should be used for partitioning. This is assessed using a score function, 
?̂? =  𝛹(𝑌𝑖, 𝜃), for systematic deviations from their mean 0 over possible covariates. These 
deviations are captured by the empirical fluctuation of the process21  
𝑊𝑗(𝑡) =  𝐽
−1/2 𝑛−1/2  ∑  ?̂?𝜎(𝑋𝑖𝑗)
⌊𝑛𝑡⌋
𝑖=1
            (0 ≤ 𝑡 ≤ 1) 
where 𝜎(𝑥𝑖𝑗) is the ordering permutation which gives the antirank of the observation 𝑋𝑖𝑗 in the 
vector of covariates 𝑋𝑗, and 𝐽 is the covariance matrix 𝐶𝑜𝑣 (𝛹(𝑌𝑖 , 𝜃)). This framework of testing 
parameter stability is established by Zeileis et al.30  
If the overall null hypothesis of no instability (for any of the parameters) is not rejected, 
we assume there are no (further) subgroups.29 However, if the null hypothesis is rejected, this 
implies there is instability. Then, the variable with the smallest p-value will have the highest 
parameter instability. Further, the sample is partitioned into subgroups with respect to this split 
variable using a binary split. When more than two splits are possible, the split which minimizes 
the objective function of the model in the two resulting subgroups will be chosen.29 Then the new 
model will be fitted in each subgroup, and the parameters of each model will be tested again for 
instability. This process is repeated until no more parameter instability is observed, or minimum 
sample is reached. MOB uses Bonferroni correction to adjust for multiple testing. We used 
‘partykit’ package and glmtree function in R to implement model-based Recursive Partitioning.  
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Sensitivity Analysis adjusting for heart rate and blood pressure  
Since only 39% of the non-traumatic SAH patient’s heart rate and blood pressure values were 
available, a separate analysis on subjects (n= 940) was conducted to adjust for these variables. 
Results 
 
Summary Statistics 
 
The baseline characteristics of 2415 non-traumatic SAH patients are displayed in Table 1. Besides 
demographic and vital sign factors, 750 pretreatment medication variables were also considered in 
our analysis. Since the medical diagnoses such as heart disease and diabetes were unknown before 
or after the vasopressor treatment, we assumed that the pretreatment medications would capture 
the clinical subgroups. Except for gender, most of the baseline characteristics had a statistically 
significant difference between the treatment groups. 
Table 1: Baseline characteristics of non-traumatic SAH patients by vasopressor treatment group 
Characteristic 
N (%) 
Total 
2415 
Phenylephrine 
1251 (51.8) 
Dopamine 
492 (20.3) 
Norepinephrine 
672 (27.8) 
p-value 
<0.001 
Age, years, mean (SD) 
56.5 
(14.8) 
56.28 
(14.34) 
58.1 
(15.4) 
55.62 
(15.16) 
0.021 
Male Sex, n (%) 
879 
(36.4) 
459 
(36.6) 
172 
(34.9) 
248 
(36.9) 
0.75 
Race, n (%)     <0.001 
  African American 
549 
(22.7) 
243 
(19.4) 
114 
(23.1) 
192 
(28.5) 
 
 White 
1609 
(66.6) 
867 
(69.3) 
325 
(66.0) 
417 
(62.0) 
 
 Other 
257 
(10.6) 
141  
(11.2) 
53  
(10.7) 
63  
(9.4) 
 
Marital Status, n (%)     0.004 
  Divorced 
258 
(10.6) 
133  
(10.6) 
46  
(9.3) 
79  
(11.7) 
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  Married 
1098 
(45.4) 
576 
 (46.0) 
225 
 (45.7) 
297  
(44.2) 
 
  Single 
637 
(26.4) 
327  
(26.1) 
113  
(22.9) 
197 
 (29.3) 
 
  Widowed 
180 
(7.4) 
79 
 (6.3) 
48  
(9.7) 
53  
(7.8) 
 
  Unknown 
242 
(10.0) 
136  
(10.8) 
60  
(12.2) 
46 
 (6.8) 
 
Mortality, n (%) 
879 
(36.4) 
317  
(25.3) 
251  
(51.0) 
311  
(46.2) 
<0.001 
Blood pressure (mmHg), 
mean (SD) 
     
  Systolic* 
122.6 
(28.8) 
126.34 (27.17) 
115.31 
(31.74) 
117.44 
(29.99) 
<0.001 
  Diastolic* 
65.6 
(16.2) 
66.87 
(15.08) 
65.41 
(17.31) 
63.06 
(17.7) 
<0.001 
Heart Rate, mean* (SD) 
84.14 
(21.76) 
80.44 
(18.75) 
82.94 
(23.65) 
91.96 
(24.63) 
<0.001 
* calculated for subsample n=940 
Multinomial lasso and GBM 
The first objective in our analysis was to create covariate balanced data. For this purpose, we 
conducted variable selection using L1-penalized generalized linear models prior to GBM. We used 
the cv.glmnet function in R with 10-fold cross validation to estimate an optimal value of 𝜆.  The 
prediction error curve as a function of 𝜆 is shown in Figure 1. We chose the 𝜆 = 0 .012 that yielded 
the lowest cross-validated prediction error. After the initial multinomial lasso variable selection 
for the treatment model, 159 out of 750 medication covariates were selected along with paitents’ 
age, race and marital status. We included all these selected factors into GBM to generate a 
propensity score model and the corresponding IPTWs. The ‘mnps’ function in the twang package 
was used with parameter settings of “n.trees” = 6000, “estimand” = ATE and “stop.method”= 
"es.mean", "ks.mean". Figure 2 shows the graphical assessment of balance achieved through 
inverse probability treatment weighting. Figure 2a shows that maximum absolute standardized 
mean difference (AMSD) decreases for all pretreatment covariates after weighting for both 
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stopping rules. As a rule of thumb, AMSD less than 0.2 is required to achieve a good balance. In 
our case, after weighting, AMSD less than 0.3 is achieved, which could be considered as a 
moderate to good balance.26 The Figure 2b shows that pairwise minimum p-values increased after 
propensity score weighting (hollow circle). The 45-degree line in this figure shows qline 
corresponds to the quantiles in the uniform distribution. When the null  hypothesis is true, the p-
values from the independent test should follow a uniform distribution.31 The large deviation of the 
solid circle from this 45-degree line shows the lack of balance before weighting. After weighting, 
the fact that the p-value has been brought closer to the 45-degree line confirms there was an 
improvement in covariate balance between the treatment groups. 
Figure 1: Plot of the misclassification error and the number of variables in the model as functions 
of -log( λ) for the 10-fold cross-validation analyses. The lowest point in the curve indicates the 
optimal lambda. 
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Figure 2a: The maximum pairwise absolute standardized mean differences of the pretreatment 
covariates before and after weighting based on es.mean and ks.mean stopping rule. 
 
Figure 2b: QQ plot comparing the quantiles of the observed p-values to the quantiles of the 
uniform distribution 
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Subgroup Analysis: Binary lasso and Interaction studies 
 
After constructing balanced data, we proceeded with subgroup analysis. At first, we conducted 
variable selection using L1-penalized generalized linear models. However, here we were only 
interested in finding covariates associated with mortality. So, we used cv.glmnet with 10-fold 
crossvalidation and estimated an optimal value of λ. We observed that age, total fluids 
administered, and vasopressor treatment were associated with mortality. Additionally, 58 out of 
the 750 pretreatment medications were associated with mortality. Utilizing these significant 
factors, the base model was constructed as below: 
Pr(𝑀𝑜𝑟𝑡𝑎𝑙𝑖𝑡𝑦 = 1|𝑋) = 𝛽0 +  𝛽1𝐷𝑜𝑝𝑎𝑚𝑖𝑛𝑒 +  𝛽2𝑁𝑜𝑟𝑒𝑝𝑖𝑛𝑒𝑝ℎ𝑟𝑖𝑛𝑒 + 𝛽3𝑋𝑐1 +  … . . +𝛽63𝑋𝑐60 
 where 𝑋𝑐1 … . 𝑋𝑐60 represent selected covariates using lasso penalized feature selection. Further, 
with respect to each selected 60 covariates, 60 interaction models were constructed as follows: 
Interaction model 1: 
Pr(𝑀𝑜𝑟𝑡𝑎𝑙𝑖𝑡𝑦 = 1|𝑋)
= 𝛽0 +  𝛽1𝐷𝑜𝑝𝑎𝑚𝑖𝑛𝑒 +  𝛽2𝑁𝑜𝑟𝑒𝑝𝑖𝑛𝑒𝑝ℎ𝑟𝑖𝑛𝑒 + 𝛽3𝑋𝑐1 +  … . . +𝛽63𝑋𝑐60
+ 𝛽64𝐷𝑜𝑝𝑎𝑚𝑖𝑛𝑒 × 𝑋𝑐1 +  𝛽65𝑁𝑜𝑟𝑒𝑝𝑖𝑛𝑒𝑝ℎ𝑟𝑖𝑛𝑒 × 𝑋𝑐1  
Interaction model 60: 
Pr(𝑀𝑜𝑟𝑡𝑎𝑙𝑖𝑡𝑦 = 1|𝑋)
= 𝛽0 +  𝛽1𝐷𝑜𝑝𝑎𝑚𝑖𝑛𝑒 +  𝛽2𝑁𝑜𝑟𝑒𝑝𝑖𝑛𝑒𝑝ℎ𝑟𝑖𝑛𝑒 + 𝛽3𝑋𝑐1 +  … . . +𝛽63𝑋𝑐60
+ 𝛽64𝐷𝑜𝑝𝑎𝑚𝑖𝑛𝑒 × 𝑋𝑐60 +  𝛽65𝑁𝑜𝑟𝑒𝑝𝑖𝑛𝑒𝑝ℎ𝑟𝑖𝑛𝑒 × 𝑋𝑐60  
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We used svyglm function in R to incorporate with IPTW obtained from GBM. Further, a likelihood 
ratio test was used to compare the base model with each interaction model.  In order to account for 
multiple comparisons, we used the FDR correction procedure. The results indicated that only 
pretreatment medication of amitriptyline (Med_lable_34563) had significant vasopressor-
medication interaction. Table 2 shows the coefficient estimate and the p-value for the significant 
interaction model.  
Further, in order to understand the vasopressor effect in the presence and absence of amitriptyline, 
we calculated various effects as shown in  Table 3. Utilizing these effects, we calculated the odds 
ratio and the corresponding confidence interval. For instance, the odds ratio comparing dopamine 
to phenylephrine among those who had amitriptyline was calculated by subtracting effect (4) – 
effect (2). Similarly, the odds ratio comparing norepinephrine to phenylephrine among those who 
had amitriptyline was calculated by subtracting effect (6) – effect (2). Likewise, effect (3) –effect 
(1) gave the odds ratio comparing dopamine to phenylephrine among those who did not have 
amitriptyline.  Besides, to find the odds ratio comparing norepinephrine to phenylephrine among 
those who did not have amitriptyline, we subtracted the effect (1) from effect (5). The results are 
shown as a forest plot in Figure 3. 
Table 2: Coefficient estimate (p-value) for outcome model fitted with IPTW, vasopressor 
treatment indicator (with ref: phenylephrine) and its interaction term with amitriptyline after 
adjusting for pretreatment variables. 
Effects Model with Vasopressor- amitriptyline interaction 
Intercept 0.47 (<0.001) 
Dopamine 0.129 (<0.001) 
Norepinephrine 0.125 (<0.001) 
Amitriptyline 0.269 (<0.001) 
Dopamine× Amitriptyline -0.49(<0.001) 
Norepinephrine× Amitriptyline Not estimated due to small sample sizes 
27 
 
 
Table 3: Calculation of various treatment effect based on the interaction model. 
Effect Vasopressor 
Pretreatment Medication (Prt Med.) 
(Each variable from 𝑋𝑐1 , … , 𝑋𝐶60 with 
corresponding coefficients 𝛽3, … , 𝛽63) 
Logit(P(Y=1) where  
the coefficient for 
Prt Med is 
represented as 𝛽𝑖 
1 Phenylephrine (Ph) Not given 𝛽0 
2 Phenylephrine (Ph) Given 𝛽0 + 𝛽𝑖 
3 Dopamine (Do) Not given 𝛽0 + 𝛽1 
4 Dopamine (Do) Given 𝛽0 + 𝛽1 + 𝛽𝑖 + 𝛽64 
5 Norepinephrine (Nor) Not given 𝛽0 + 𝛽2 
6 Norepinephrine (Nor) Given 𝛽0 + 𝛽2 + 𝛽𝑖 + 𝛽65 
The results showed that dopamine and norepinephrine had higher mortality compared to 
phenylephrine based on the base model without interaction. The odds ratio of mortality of 
dopamine compared to that of phenylephrine among those who had amitriptyline was 0.69, and 
95% CI was (0.55,0.88); however, the odds ratio among those who did not have amitriptyline was  
1.13, and 95% CI was (1.08, 1.19). We did not observe a statistically significant interaction effect 
between amitriptyline and norepinephrine. When we examined the number of subjects who had 
amitriptyline stratified by the type of vasopressor and mortality (Table 5), the results showed that 
amitriptyline was never administered to the subjects who had norepinephrine. 
Table 4: The OR and 95% confidence interval for the association of treatment with mortality 
using IPTW after adjusting for pretreatment variables 
Effects OR (95% Confidence interval) 
For the base model without interaction   
Dopamine 1.13 (1.07, 1.19) 
Norepinephrine 1.13 (1.08, 1.18) 
Phenylephrine Ref Ref 
Amitriptyline given   
Dopamine 0.69 (0.55, 0.88) 
Norepinephrine Not estimated due to small sample sizes 
Phenylephrine Ref Ref 
Amitriptyline not given   
Dopamine 1.13 (1.08, 1.19) 
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Norepinephrine 1.13 (1.08, 1.18) 
Phenylephrine Ref Ref 
 
Figure 3: Forest plot showing odds ratios and confidence interval comparing dopamine and 
norepinephrine to phenylephrine, in presence and absence of amitriptyline. 
 
* Odds ratio for the base model without interaction. ~ Odds ratio for amitriptyline interaction model. All odds ratio is adjusted for 
significant pretreatment covariates from the lasso model. 
 
Table 5: The number of subjects who had amitriptyline stratified by type of vasopressor and 
mortality 
Mortality 
 amitriptyline 
Vasopressor Not given Given 
Survived 
phenylephrine 926 8 
dopamine 240 1 
norepinephrine 361 0 
Dead 
phenylephrine 309 8 
dopamine 251 0 
norepinephrine 311 0 
Subsample analysis 
As described above, subgroup analysis was repeated on complete cases (N=940) for which heart 
rate and blood pressure values were available. After conducting the propensity score modeling, 
covariate balance was assessed, and a balance as in  shown Figure 2a and 2b was observed. Further, 
the lasso and interaction effect analysis were conducted. In subsample analysis, none of the 
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medications was observed to have a significant interaction effect with the vasopressor treatment 
group. 
Model-based Recursive Partitioning (MOB)  
We used MOB, a machine learning approach to capture the differential vasopressor treatment 
effect across the subgroups. In order to implement MOB, we utilized glmtree function in R. To 
account for covariate imbalance within the data, we used IPTW calculated through GBM.  As 
shown in Figure 4, for sample size N=2,415, ondansetron, fentanyl, mannitol, lidocaine, and age 
were the partitioning variables selected for the tree. The terminal node in Figure 4 has a boxplot 
comparing mortality (as y) across the vasopressor treatment group (as x) for that subgroup. The 
fitted lines are the mean predicted probabilities in each group. Since automatically generated 
boxplot is unclear, Table 6 is included to show the distribution of the number of subjects for each 
subgroup stratified by treatment and mortality.  
The results showed that among those who had ondansetron, the treatment effect on 
mortality followed a similar pattern across the age subgroups: phenylephrine was associated with 
lower odds of mortality, and norepinephrine was associated with higher odds of mortality. 
Moreover, it can be observed that across all terminal nodes, the rate of mortality was lower among 
those who had ondansetron compared those who did not have ondansetron. Between all nodes, 
phenylephrine was consistently observed to be associated with lower mortality, and dopamine 
seemed to be associated with higher odds of mortality among those who did not have ondansetron. 
In Figure 5, an equivalent observation was found for a subsample (n=940). Based on the subsample 
data consisting of complete cases with heart rate and blood pressure values, the significant 
subgroup was identified only with the pretreatment medication of ondansetron. The mortality is 
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much lower among those who had ondansetron where phenylephrine was associated with lower 
odds of mortality. Among those who had ondansetron, norepinephrine was associated with higher 
odds of mortality. However, among those who did not have ondansetron, dopamine was associated 
with higher odds of mortality. 
Figure 4: Logistic-regression-based tree for the n= 2,415. The plots in the leaves show boxplot 
for mortality by vasopressor treatment group 
 
Table 6: Number of subjects for each subgroup stratified by treatment and mortality 
Node Mortality Phenylephrine dopamine norepinephrine N 
4 0 155 61 71 666 
1 97 141 141 
5 0 23 12 5 156 
1 50 38 28 
7 0 112 21 61 348 
1 72 31 51 
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8 0 125 30 50 265 
1 36 12 12 
10 0 423 90 152 776 
1 36 19 56 
11 0 96 27 22 204 
1 26 10 23 
 
Figure 5: Logistic-regression-based tree for the n = 940. The plots in the leaves show boxplots 
for mortality by vasopressor treatment group 
 
Discussion 
 
A previous study on Cerner-based SAH patient records showed that among the three 
vasopressors, dopamine, phenylephrine, and norepinephrine, phenylephrine administration has 
been associated with a lower rate in mortality. On this account, we were interested in investigating 
if this overall effect was generalizable to all SAH patients. In order to examine this, a subgroup 
analysis was conducted to study the differential vasopressor treatment effect among the SAH 
patients. We performed subgroup analysis through a generalized linear model and a machine 
learning tree-based approach. 
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Pretreatment administration of ondansetron was a significant factor since it had a 
differential treatment effect based on the tree-based method. Ondansetron is selective serotonin 5-
HT3 (5- hydroxytryptophan 3) antagonist that is used to prevent nausea and vomiting associated 
with several conditions including anesthesia and surgery.32 Based on the mob results (Figures 4 
and 5), among those who had ondansetron, the predicted probability of mortality is lower 
compared to those who did not have ondansetron after controlling for the vasopressor treatment 
group.  Besides among those who had ondansetron, phenylephrine was associated with the lowest 
mortality, and norepinephrine was associated with the highest mortality. Metanalysis on the effects 
of ondansetron on spinal anesthesia-induced hypotension showed that though ondansetron is 
commonly used as an antiemetic, it can  also reduce the incidence of hypotension and bradycardia 
as well as the need of vasopressor requirement.33 Our observation based on mob also aligns with 
this result: with the administration of ondansetron, norepinephrine and dopamine can be avoided 
since ondansetron along with phenylephrine has a better survival rate. However, whether 
vasopressor is required along with ondansetron needs to be further examined.  
 Based on mob analysis, we also observed that among those who had ondansetron, there 
were two subgroups by age. The SAH patients aged 66 or older had a higher probability of 
mortality compared to the younger patients. However, both age subgroups had lower mortality 
compared to those who did not have ondansetron except in one subgroup. This subgroup included 
those who did not have ondansetron but had fentanyl and lidocaine. Fentanyl is a synthetic opioid 
that is 80-100 times stronger than morphine and lidocaine, and it is an anesthetic and 
antiarrhythmic drug. Though this subgroup falls under those who did not have ondansetron, they 
had mortality in a similar range to those who had ondansetron with respect to all three 
vasopressors. 
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In contrast, amitriptyline was the only medication that was observed to be significant based 
on a generalized linear model approach. The odds ratio of mortality of dopamine compared to that 
of phenylephrine among those who had amitriptyline was lower (OR= 0.69 and 95% CI = 
0.55,0.88) compared to those who did not have amitriptyline (OR= 1.13 and 95% CI = 1.08, 1.19). 
However, this medication was administrated to only 17 out of the 2,415 subjects. Hence, the 
inference based on this result could be spurious. A literature search showed a tricyclic 
antidepressant agent, such as amitriptyline was often administrated to SAH survivors who had a 
sign of depression.36 This may indicate amitriptyline is not a pretreatment medication; however, 
for amitriptyline toxicity, vasopressor could be used to manage hypotension, even though are not 
first-line therapy. 
 On other hand, when fitting a generalized linear model on the subsample for which heart 
rate and blood pressure values are available, we did not observe any significant interactions.  A 
major difference between the generalized linear model approach and mob-based subgroup analysis 
was that, in the mob, the multiple-level interactions with treatment were studied. However, in our 
generalized model approach, we only looked at the first-order interaction since interpreting higher-
order interactions are difficult.  
This study has several limitations. First, the EHR data are retrospective, and the vasopressor 
treatments were not administered randomly. However, it would be very hard and expensive to 
address this limitation in clinical trial settings because SAH is rare. So, this database is an 
important source to investigate these questions. Second, all the important factors that led to the 
choice of the right vasopressor may not be captured in the database; therefore, there is a high 
likelihood of having not included unmeasured confounding effects such as information on clinical 
severity level and  baseline diagnostic and labs. If there are unmeasured confounding effects, the 
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exchangeability assumption for propensity modeling will be violated. Consequently, there could 
be a potential for selection bias. Of course, the medications may have captured some of these 
variables, and we observed moderate to good covariate balance after the inverse probability 
weighting. However, including any unmeasured confounders in future studies would be helpful to 
understand differential treatment with respect to morbidities and comorbidities. Third, because 
each hospital could choose what data elements to upload, the database has a high percentage of 
missing blood pressure values. In sensitivity analyses; however, we did not detect important 
differences between those that had and those who did not have blood pressure values; and when 
repeating the analysis in the subgroup that did have blood pressure, the results were mainly 
consistent.  Another limitation is that, in our analysis primary exposure of interest is the first 
vasopressor administered to eligible patients, however about 6% patients were given all three 
vasopressors, and about 30% patients received a second vasopressor after the initial vasopressor. 
Since we were interested in association of mortality with first choice vasopressor, our analysis did 
not consider the second and third vasopressor administrated. But it is important acknowledge the 
fact that second and third medication also influence on vasopressor  treatment effect. 
Conclusion 
 
In this thesis, we conducted an exploratory analysis to identify subgroups within the SAH patient 
data based on their vasopressor treatment effect on mortality. The machine learning approach 
(mob) and statistical approach (GLM) generated different results. This difference, however, could 
be the result of the inherent differences of the two methodologies. In GLM, we only looked at the 
first order interaction, and we did not observe any significant interaction effect. Whereas in mob, 
higher-order interactions were studied, and significant interaction effects were observed with 
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second-degree and third-degree interactions. The mob result suggests that among those who had 
ondansetron, norepinephrine was associated with the highest mortality rate, and among those who 
did not have ondansetron, dopamine was associated with the highest mortality. For the subgroup 
who did not have ondansetron, but fentanyl and lidocaine, there is no significant difference in the 
mortality rate between the three vasopressors. Though literature suggests ondansetron can reduce 
the incidence of hypotension, ondansetron is not widely used in medical practice for this purpose, 
and hence the clinical significance of the interaction effect of an antiemetic agent such as 
ondansetron and vasopressor is not clearly understood.  It could be considered that the observed 
significant interaction effect was a marker of certain patients’ conditions. But in order to rule out 
this further analyses considering the pretreatment diagnosis and relevant lab factors are required. 
However, those who has ondansetron had better survival compared to those who did not have 
ondansetron with respect to all the three vasopressor. Besides, in general, among three 
vasopressors, phenylephrine was associated with lower mortality compared to dopamine and 
norepinephrine.  
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Appendices 
Appendix I 
Summary of variables 
 
Variables Type Number of variables/dummy 
variables 
Vasopressor treatment Categorical 2 
Medication generic names prior to 
vasopressor treatment 
Binary 750 
Age Numeric 1 
Race Categorical 2 
Gender Binary 1 
Marital status Categorical 3 
Vital signs (HR, SBP, DBP) Numeric 3 
Total fluids administered Numeric 1 
 
 
 
